The drug Emixustat has been in Phase 1/2 trials since 2008 for treatment of dry macular degeneration.
Disappointingly, the drug has now been found to be ineffective at reducing the growth rates of geographic atrophy (GA) in patients with age-related macular degeneration (AMD). Preclinical analysis of Emixustat indicated that it inhibited the activity of the RPE65 gene responsible for dysfunction of the retinal layer which nourishes the sight cells. It now appears, however, that when delivered orally in varying dosages over a 2-year period, there is no difference in GA progression among the treatment and placebo groups.
The study, “Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial,” was published online in Ophthalmology.
For information about numerous other studies still underway for treatment of dry AMD, see A Guide to Research in Dry Macular Degeneration.